Career Accelerator for Research Infrastructure Scientists

Eli Lilly and Company Ltd.


Lilly Research Laboratories (LRL) discover and develop high-quality innovative medicines that help patients live longer, healthier, happier lives. This is done in a reliable and cost-effective manner and in an atmosphere of optimism, teamwork, quality and compliance. Our investment in re- search and development has been sustained at a high level over many years and has resulted in one of the most prolific pipelines in the industry, with more than 60 potential medicines currently in development. The UK has played a big role in these advancements. The Lilly Research Centre was founded in Windlesham, Surrey in 1967. Since then, it has become a centre of excellence in neuroscience research. Today, over 600 people, representing 45 different nationalities and 30 different functional disciplines, work at Erl Wood on both discovery and development of the new potential medicines in the pipeline. Our research teams continue the quest for new medicines for neurodegenerative disorders and pain.

As a partner in this project, Eli Lilly and Company Ltd intends to cooperate with the EMBL towards training of the Fellows. Eli Lilly and Company Ltd can host up to two Fellows per year in the period 2020-2024 through secondments and introduce them to the ways of working, instrumentation and procedures at Eli Lilly and Company Ltd. Duration of secondments will be between 2 and 6 month and will be arranged in communication with the Fellow. Fellows who will do secondments at Eli Lilly and Company Ltd will come from the field related or complementary to the field of work of Eli Lilly and Company Ltd.

At Eli Lilly and Company Ltd Fellows will have a possibility to learn data science and informatics approaches to drug discovery. This includes methods for the analysis of large-scale genomics data, including tissue and single cell RNAseq, proteomics and epi-genetic data in human disease, data integration, and statistical approaches to data such as path-way, systems and network biology and machine learning as applied to drug discovery with Professor Emma Laing at Lilly. There are also opportunities with Dr Andrew McCarthy for analysis of high-dimensional, continuous behavioural and electrophysiological data in disease models, and analysis of human digital biomarker and real-world evidence, and with Dr Dave Evans in computa-tional chemistry, in areas such as the study of interaction between drugs and the genome through transcriptomics using causal reasoning. The Fellows may also have a chance to get acquainted with the operation processes such as real time, automated capture of experimental data with Re-search Information Technology at Lilly. Eli Lilly and Company Ltd will dedicate supervision capacity for each fellow on secondments. During secondments, Fellows can stay employed by EMBL.

Eli Lilly and Company Ltd intends also to host mini-secondments in a duration of up to two weeks, during which Fellows will shadow operations with the research groups mentioned above.